Cabozantinib Plus Atezolizumab As First-Line Therapy For Advanced Renal Cell Carcinoma

Cabozantinib Plus Atezolizumab as First-Line Therapy for Advanced Renal Cell Carcinoma

Cab + atezo: a new treatment for naïve advanced ccRCC

COSMIC-021: Cabozantinib + atezolizumab gives clinical activity in inoperable metastatic UC

CARINA: cabozantinib post first-line immune-oncology CPI-containing combination in aRCC

NIVO + cabozantinib vs sunitinib for first-line treatment of aRCC

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC

Cabozantinib Plus Nivolumab for First-Line mRCC

Cabozantinib for advanced renal cell carcinoma: the METEOR and CABOSUN trials

ESMO 2020 Highlights on nivolumab+cabozantinib as 1st line therapy for aRCC: The CheckMate 9ER study

European Society for Medical Oncology (ESMO)

Dr. Pal on the Safety Profile of Cabozantinib/Atezolizumab in Advanced RCC

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC

PeerView Oncology

Promising results of cabozantinib plus nivolumab in non-clear cell RCC

Dr. Toni Choueiri on Nivolumab and Cabozantinib Becoming First-Line Therapies in RCC

Targeted Oncology

FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma

CheckMate 9ER update confirms benefits of nivolumab–cabozantinib in RCC | Cristina Suárez

Medicine Matters oncology

Cohort 1 LITESPARK-003: belzutifan + cabozantinib 1L treatment for advanced RCC

CheckMate 9ER trial: nivo + cab vs sun 1L in advanced RCC

Cabozantinib most effective treatment for metastatic papillary kidney cancer

CABATEN/GETNE-T1914: cabozantinib plus atezolizumab in adrenocortical carcinoma

The Rationale for Cabozantinib in Advanced RCC